#begin document (en_2097.txt); part 000
en_2097.txt	0	0	Hope	NNP	(TOP(FRAG(NP*	-	-	-	-	*	-
en_2097.txt	0	1	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	2	Hype	NNP	*)	-	-	-	-	*	-
en_2097.txt	0	3	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	4	Personalized	NNP	(NP*	-	-	-	-	*	-
en_2097.txt	0	5	Medicine	NNP	*))	-	-	-	-	*	-
en_2097.txt	0	6	?	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	STANFORD	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	–	SYM	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	2	During	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	3	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	4	past	JJ	*	-	-	-	-	*	-
en_2097.txt	0	5	several	JJ	*	-	-	-	-	*	-
en_2097.txt	0	6	decades	NNS	*))))	-	-	-	-	*	-
en_2097.txt	0	7	,	,	*	-	-	-	-	*	-
en_2097.txt	0	8	treatment	NN	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	9	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	10	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	11	variety	NN	*)	-	-	-	-	*	-
en_2097.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	13	conditions	NNS	(NP*)))))	-	-	-	-	*	-
en_2097.txt	0	14	has	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	15	begun	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	16	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	17	shift	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	from	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	19	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	20	``	``	*	-	-	-	-	*	-
en_2097.txt	0	21	one	CD	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	22	size	NN	*)	-	-	-	-	*	-
en_2097.txt	0	23	fits	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	24	all	DT	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	25	''	''	*	-	-	-	-	*	-
en_2097.txt	0	26	approach	NN	*)	-	-	-	-	*	-
en_2097.txt	0	27	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	28	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	29	more	RBR	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	30	personalized	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	31	strategy	NN	*)))))))))	-	-	-	-	*	-
en_2097.txt	0	32	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	2	result	NN	*))	-	-	-	-	*	-
en_2097.txt	0	3	,	,	*	-	-	-	-	*	-
en_2097.txt	0	4	patients	NNS	(NP*)	-	-	-	-	*	(0)
en_2097.txt	0	5	can	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	6	more	RBR	(ADVP*	-	-	-	-	*	-
en_2097.txt	0	7	often	RB	*)	-	-	-	-	*	-
en_2097.txt	0	8	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	9	matched	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	the	DT	(NP(NP(NP*	-	-	-	-	*	(1
en_2097.txt	0	12	best	JJS	*	-	-	-	-	*	-
en_2097.txt	0	13	drug	NN	*)	-	-	-	-	*	-
en_2097.txt	0	14	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	their	PRP$	(NP*	-	-	-	-	*	(0)
en_2097.txt	0	16	genetic	JJ	*	-	-	-	-	*	-
en_2097.txt	0	17	makeup	NN	*)))	-	-	-	-	*	-
en_2097.txt	0	18	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	19	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	20	exact	JJ	*	-	-	-	-	*	-
en_2097.txt	0	21	subcategory	NN	*)	-	-	-	-	*	-
en_2097.txt	0	22	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	23	their	PRP$	(NP*	-	-	-	-	*	(0)
en_2097.txt	0	24	disease	NN	*))))))))	-	-	-	-	*	1)
en_2097.txt	0	25	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	This	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	1	enables	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	2	physicians	NNS	(NP*)	-	-	-	-	*	-
en_2097.txt	0	3	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	4	avoid	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	prescribing	VBG	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	6	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	7	medication	NN	*)	-	-	-	-	*	-
en_2097.txt	0	8	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2097.txt	0	9	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	10	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	11	dosage	NN	*)	-	-	-	-	*	-
en_2097.txt	0	12	-RRB-	-RRB-	*)	-	-	-	-	*	-
en_2097.txt	0	13	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	14	might	MD	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	15	cause	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	16	serious	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	17	side	NN	*	-	-	-	-	*	-
en_2097.txt	0	18	effects	NNS	*))))))))	-	-	-	-	*	-
en_2097.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	20	certain	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	21	populations	NNS	*))))))	-	-	-	-	*	-
en_2097.txt	0	22	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	other	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	2	words	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	3	,	,	*	-	-	-	-	*	-
en_2097.txt	0	4	even	RB	(PP*	-	-	-	-	*	-
en_2097.txt	0	5	among	IN	*	-	-	-	-	*	-
en_2097.txt	0	6	patients	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	7	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	8	apparently	RB	(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	9	have	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	11	same	JJ	*	-	-	-	-	*	-
en_2097.txt	0	12	disease	NN	*	-	-	-	-	*	-
en_2097.txt	0	13	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	14	symptoms	NNS	*))))))	-	-	-	-	*	-
en_2097.txt	0	15	,	,	*	-	-	-	-	*	-
en_2097.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	17	treatment	NN	*)	-	-	-	-	*	-
en_2097.txt	0	18	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	19	each	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	20	one	CD	*)))	-	-	-	-	*	-
en_2097.txt	0	21	would	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	22	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	23	determined	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	24	by	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	25	various	JJ	(NP*	-	-	-	-	*	(2
en_2097.txt	0	26	predictive	JJ	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	27	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	28	prognostic	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	29	tests	NNS	*)))))	-	-	-	-	*	2)
en_2097.txt	0	30	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Eventually	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	these	DT	(NP*	-	-	-	-	*	(2
en_2097.txt	0	3	tests	NNS	*)	-	-	-	-	*	2)
en_2097.txt	0	4	could	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	extend	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	6	even	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	7	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	9	sequencing	NN	*)	-	-	-	-	*	-
en_2097.txt	0	10	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	12	DNA	NN	*))))	-	-	-	-	*	-
en_2097.txt	0	13	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	14	an	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	15	individual	JJ	*	-	-	-	-	*	-
en_2097.txt	0	16	patient	NN	*	-	-	-	-	*	-
en_2097.txt	0	17	'	POS	*)	-	-	-	-	*	-
en_2097.txt	0	18	s	JJ	*	-	-	-	-	*	-
en_2097.txt	0	19	cancer	NN	*	-	-	-	-	*	-
en_2097.txt	0	20	cells	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	21	,	,	*	-	-	-	-	*	-
en_2097.txt	0	22	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	23	example	NN	(NP*))))	-	-	-	-	*	-
en_2097.txt	0	24	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	while	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	3	this	DT	(S(NP*	-	-	-	-	*	(3
en_2097.txt	0	4	high-tech	JJ	*	-	-	-	-	*	-
en_2097.txt	0	5	approach	NN	*)	-	-	-	-	*	3)
en_2097.txt	0	6	could	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	8	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	9	boon	NN	*)	-	-	-	-	*	-
en_2097.txt	0	10	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	patients	NNS	(NP*)))))))	-	-	-	-	*	-
en_2097.txt	0	12	,	,	*	-	-	-	-	*	-
en_2097.txt	0	13	it	PRP	(NP*)	-	-	-	-	*	(3)
en_2097.txt	0	14	could	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	15	prove	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	16	detrimental	JJ	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	17	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	18	drug	NN	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	19	companies	NNS	*	-	-	-	-	*	-
en_2097.txt	0	20	'	POS	*)	-	-	-	-	*	-
en_2097.txt	0	21	bottom	JJ	*	-	-	-	-	*	-
en_2097.txt	0	22	lines	NNS	*)))))	-	-	-	-	*	-
en_2097.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_2097.txt	0	1	reasons	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	2	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	subtle	JJ	(ADJP*))	-	-	-	-	*	-
en_2097.txt	0	4	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Personalized	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_2097.txt	0	1	drug	NN	*	-	-	-	-	*	-
en_2097.txt	0	2	therapy	NN	*)	-	-	-	-	*	-
en_2097.txt	0	3	uses	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	4	biological	JJ	(NP(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	5	indicators	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	6	,	,	*	-	-	-	-	*	-
en_2097.txt	0	7	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	8	``	``	(NP*	-	-	-	-	*	-
en_2097.txt	0	9	biomarkers	NNS	(NP*)	-	-	-	-	*	-
en_2097.txt	0	10	''	''	*	-	-	-	-	*	-
en_2097.txt	0	11	–	SYM	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	12	such	JJ	(PP*	-	-	-	-	*	-
en_2097.txt	0	13	as	IN	*	-	-	-	-	*	-
en_2097.txt	0	14	DNA	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	15	sequences	NNS	*)))))	-	-	-	-	*	-
en_2097.txt	0	16	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	17	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	18	presence	NN	*	-	-	-	-	*	-
en_2097.txt	0	19	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	20	absence	NN	*)	-	-	-	-	*	-
en_2097.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	22	drug	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	23	receptors	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	24	–	SYM	(UCP(PP(X*)	-	-	-	-	*	-
en_2097.txt	0	25	as	IN	*	-	-	-	-	*	-
en_2097.txt	0	26	an	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	27	indicator	NN	*)	-	-	-	-	*	-
en_2097.txt	0	28	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	29	how	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_2097.txt	0	30	patients	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	31	should	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	32	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	33	treated	VBN	(VP*))))))))	-	-	-	-	*	-
en_2097.txt	0	34	,	,	*	-	-	-	-	*	-
en_2097.txt	0	35	as	RB	(CONJP*	-	-	-	-	*	-
en_2097.txt	0	36	well	RB	*	-	-	-	-	*	-
en_2097.txt	0	37	as	IN	*)	-	-	-	-	*	-
en_2097.txt	0	38	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	39	estimate	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	40	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	41	likelihood	NN	*	-	-	-	-	*	-
en_2097.txt	0	42	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	43	the	DT	(S(NP*	-	-	-	-	*	(4
en_2097.txt	0	44	intervention	NN	*)	-	-	-	-	*	4)
en_2097.txt	0	45	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	46	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	47	effective	JJ	(ADJP*)))))))))))))	-	-	-	-	*	-
en_2097.txt	0	48	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	This	DT	(TOP(S(S(NP*	-	-	-	-	*	(5
en_2097.txt	0	1	concept	NN	*)	-	-	-	-	*	5)
en_2097.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	not	RB	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	4	new	JJ	*)))	-	-	-	-	*	-
en_2097.txt	0	5	:	:	*	-	-	-	-	*	-
en_2097.txt	0	6	it	PRP	(S(NP*)	-	-	-	-	*	(5)
en_2097.txt	0	7	has	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	8	been	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	9	known	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	decades	NNS	(NP*))	-	-	-	-	*	-
en_2097.txt	0	12	,	,	(PRN*	-	-	-	-	*	-
en_2097.txt	0	13	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	14	example	NN	(NP*))	-	-	-	-	*	-
en_2097.txt	0	15	,	,	*)	-	-	-	-	*	-
en_2097.txt	0	16	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	17	people	NNS	(S(NP(NP*)	-	-	-	-	*	(6
en_2097.txt	0	18	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	19	have	VBP	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	20	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	21	genetic	JJ	*	-	-	-	-	*	-
en_2097.txt	0	22	deficiency	NN	*)	-	-	-	-	*	-
en_2097.txt	0	23	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	24	an	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	25	enzyme	NN	*)	-	-	-	-	*	-
en_2097.txt	0	26	called	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	G6PD	JJ	(S(ADJP*))))))))))	-	-	-	-	*	6)
en_2097.txt	0	28	can	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	29	experience	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	30	severe	JJ	(NP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	31	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	32	precipitous	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	33	anemia	NN	*)	-	-	-	-	*	-
en_2097.txt	0	34	if	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	35	they	PRP	(S(NP*)	-	-	-	-	*	(6)
en_2097.txt	0	36	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	37	exposed	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	38	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	39	certain	JJ	(NP*	-	-	-	-	*	(7
en_2097.txt	0	40	drugs	NNS	*))))))))))))))	-	-	-	-	*	7)
en_2097.txt	0	41	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Similarly	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	ethnic	JJ	(NP(NP*	-	-	-	-	*	(8
en_2097.txt	0	3	groups	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	4	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	5	individuals	NNS	(NP*))	-	-	-	-	*	8)
en_2097.txt	0	6	vary	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	widely	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	8	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	9	their	PRP$	(NP*	-	-	-	-	*	(8)
en_2097.txt	0	10	ability	NN	*	-	-	-	-	*	-
en_2097.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	12	clear	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	13	medications	NNS	(NP*)	-	-	-	-	*	-
en_2097.txt	0	14	from	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	16	bloodstream	NN	*)))))))	-	-	-	-	*	-
en_2097.txt	0	17	,	,	*	-	-	-	-	*	-
en_2097.txt	0	18	owing	VBG	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	20	differences	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	21	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	22	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	23	activity	NN	*)	-	-	-	-	*	-
en_2097.txt	0	24	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	25	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	26	enzymes	NNS	*))))	-	-	-	-	*	-
en_2097.txt	0	27	that	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	28	metabolize	JJ	(NP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	29	,	,	*	-	-	-	-	*	-
en_2097.txt	0	30	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	31	degrade	JJ	*	-	-	-	-	*	-
en_2097.txt	0	32	,	,	*)	-	-	-	-	*	-
en_2097.txt	0	33	drugs	NNS	*)))))))	-	-	-	-	*	-
en_2097.txt	0	34	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	That	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	1	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	2	important	JJ	(ADJP*)	-	-	-	-	*	-
en_2097.txt	0	3	because	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	4	low	JJ	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	5	metabolizers	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	6	clear	VB	(VP(VP*	-	-	-	-	*	-
en_2097.txt	0	7	certain	JJ	(NP*	-	-	-	-	*	(7
en_2097.txt	0	8	drugs	NNS	*)	-	-	-	-	*	7)
en_2097.txt	0	9	slowly	RB	(ADVP*))	-	-	-	-	*	-
en_2097.txt	0	10	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	11	have	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	more	JJR	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	13	medication	NN	*)	-	-	-	-	*	-
en_2097.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	their	PRP$	(NP*	-	-	-	-	*	(7)
en_2097.txt	0	16	systems	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	17	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	18	longer	JJR	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	19	periods	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	20	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	21	time	NN	(NP*))	-	-	-	-	*	-
en_2097.txt	0	22	than	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	23	high	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	24	metabolizers	NNS	*))))))))))	-	-	-	-	*	-
en_2097.txt	0	25	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Thus	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	3	former	NN	*)	-	-	-	-	*	-
en_2097.txt	0	4	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	6	prone	JJ	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	7	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	overdose	NN	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	9	,	,	*	-	-	-	-	*	-
en_2097.txt	0	10	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	12	latter	JJ	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	13	to	TO	*	-	-	-	-	*	-
en_2097.txt	0	14	insufficient	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	15	levels	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	17	the	DT	(NP*	-	-	-	-	*	(1
en_2097.txt	0	18	same	JJ	*	-	-	-	-	*	-
en_2097.txt	0	19	drug	NN	*))))))))	-	-	-	-	*	1)
en_2097.txt	0	20	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Prognostic	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_2097.txt	0	1	biomarkers	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	2	have	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	begun	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	4	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	5	make	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	6	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	7	big	JJ	*	-	-	-	-	*	-
en_2097.txt	0	8	difference	NN	*)	-	-	-	-	*	-
en_2097.txt	0	9	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	10	cancer	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	11	therapy	NN	*))))))))	-	-	-	-	*	-
en_2097.txt	0	12	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Drugs	NNS	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	1	such	JJ	(PP*	-	-	-	-	*	-
en_2097.txt	0	2	as	IN	*	-	-	-	-	*	-
en_2097.txt	0	3	Erbitux	NNP	(NP*	-	-	-	-	*	-
en_2097.txt	0	4	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	5	Vectibix	NNP	*)))	-	-	-	-	*	-
en_2097.txt	0	6	work	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	only	RB	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	in	IN	*	-	-	-	-	*	-
en_2097.txt	0	9	tumors	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	10	containing	VBG	(VP*	-	-	-	-	*	-
en_2097.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	12	normal	JJ	*	-	-	-	-	*	-
en_2097.txt	0	13	version	NN	*)	-	-	-	-	*	-
en_2097.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	16	gene	NN	*)	-	-	-	-	*	-
en_2097.txt	0	17	called	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	KRAS	NNP	(S(NP*))))))))))	-	-	-	-	*	(9)
en_2097.txt	0	19	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	If	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_2097.txt	0	1	mutations	NNS	(S(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	2	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	3	KRAS	NNS	(NP*)))	-	-	-	-	*	(9)
en_2097.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	present	JJ	(ADJP*))))	-	-	-	-	*	-
en_2097.txt	0	6	,	,	*	-	-	-	-	*	-
en_2097.txt	0	7	the	DT	(NP*	-	-	-	-	*	(7
en_2097.txt	0	8	drugs	NNS	*)	-	-	-	-	*	7)
en_2097.txt	0	9	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	ineffective	JJ	(ADJP*))	-	-	-	-	*	-
en_2097.txt	0	11	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Such	JJ	(TOP(S(S(NP*	-	-	-	-	*	-
en_2097.txt	0	1	mutations	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	2	explain	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	about	RB	(NP(NP(QP*	-	-	-	-	*	-
en_2097.txt	0	4	30-40	CD	*)	-	-	-	-	*	-
en_2097.txt	0	5	%	NN	*)	-	-	-	-	*	-
en_2097.txt	0	6	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	7	cases	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	8	in	IN	(SBAR(WHPP*	-	-	-	-	*	-
en_2097.txt	0	9	which	WDT	(WHNP*))	-	-	-	-	*	-
en_2097.txt	0	10	patients	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	11	fail	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	13	respond	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	14	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	these	DT	(NP*	-	-	-	-	*	(7
en_2097.txt	0	16	drugs	NNS	*)))))))))))))	-	-	-	-	*	7)
en_2097.txt	0	17	,	,	*	-	-	-	-	*	-
en_2097.txt	0	18	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	19	mutations	NNS	(S(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	20	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	21	another	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	22	gene	NN	*)	-	-	-	-	*	-
en_2097.txt	0	23	called	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	24	BRAF	NNP	(S(NP*))))))	-	-	-	-	*	-
en_2097.txt	0	25	could	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	26	account	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	28	another	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	29	12	CD	*	-	-	-	-	*	-
en_2097.txt	0	30	%	NN	*)))))	-	-	-	-	*	-
en_2097.txt	0	31	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Knowing	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_2097.txt	0	1	this	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	2	crucial	JJ	*	-	-	-	-	*	-
en_2097.txt	0	3	information	NN	*)	-	-	-	-	*	-
en_2097.txt	0	4	about	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	5	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	6	cancer	NN	*	-	-	-	-	*	-
en_2097.txt	0	7	patient	NN	*	-	-	-	-	*	-
en_2097.txt	0	8	'	POS	*)	-	-	-	-	*	-
en_2097.txt	0	9	s	JJ	*	-	-	-	-	*	-
en_2097.txt	0	10	genes	NNS	*)))))	-	-	-	-	*	-
en_2097.txt	0	11	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	reduce	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	13	sharply	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	15	number	NN	*)	-	-	-	-	*	-
en_2097.txt	0	16	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	17	are	VBP	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	18	unnecessarily	RB	(VP(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	19	subjected	VBN	*	-	-	-	-	*	-
en_2097.txt	0	20	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	21	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	22	side	NN	*	-	-	-	-	*	-
en_2097.txt	0	23	effects	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	24	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2097.txt	0	25	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	26	expense	NN	(NP*)	-	-	-	-	*	-
en_2097.txt	0	27	-RRB-	-RRB-	*)	-	-	-	-	*	-
en_2097.txt	0	28	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	29	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	30	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	31	will	MD	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	32	not	RB	*	-	-	-	-	*	-
en_2097.txt	0	33	work	VB	(VP*)))))))))))))))	-	-	-	-	*	-
en_2097.txt	0	34	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Improving	VBG	(TOP(SINV(S(S(VP(VP*	-	-	-	-	*	-
en_2097.txt	0	1	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	2	efficacy	NN	*))	-	-	-	-	*	-
en_2097.txt	0	3	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	4	reducing	VBG	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	6	side	NN	*	-	-	-	-	*	-
en_2097.txt	0	7	effects	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	9	drug	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	10	therapy	NN	*))))))	-	-	-	-	*	-
en_2097.txt	0	11	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	13	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	14	boon	NN	*)	-	-	-	-	*	-
en_2097.txt	0	15	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	16	doctors	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	17	,	,	*	-	-	-	-	*	-
en_2097.txt	0	18	patients	NNS	(NP*)	-	-	-	-	*	-
en_2097.txt	0	19	,	,	*	-	-	-	-	*	-
en_2097.txt	0	20	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	21	insurance	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	22	companies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	23	,	,	*))	-	-	-	-	*	-
en_2097.txt	0	24	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	25	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	26	sure	JJ	(ADJP*))))))))	-	-	-	-	*	-
en_2097.txt	0	27	,	,	*	-	-	-	-	*	-
en_2097.txt	0	28	but	CC	*	-	-	-	-	*	-
en_2097.txt	0	29	why	WRB	(SBARQ(WHADVP*)	-	-	-	-	*	-
en_2097.txt	0	30	should	MD	(SQ*	-	-	-	-	*	-
en_2097.txt	0	31	pharmaceutical	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	32	companies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	33	embrace	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	34	personalized	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	35	medicine	NN	*)	-	-	-	-	*	-
en_2097.txt	0	36	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	37	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	38	long	JJ	*	-	-	-	-	*	-
en_2097.txt	0	39	term	NN	*))))	-	-	-	-	*	-
en_2097.txt	0	40	?	.	*)))	-	-	-	-	*	-

en_2097.txt	0	0	On	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	2	positive	JJ	*	-	-	-	-	*	-
en_2097.txt	0	3	side	NN	*))	-	-	-	-	*	-
en_2097.txt	0	4	,	,	*	-	-	-	-	*	-
en_2097.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	6	presence	NN	*)	-	-	-	-	*	-
en_2097.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	biomarkers	NNS	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	9	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	enable	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	11	drug	NN	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	12	companies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	13	to	TO	(VP*	-	-	-	-	*	-
en_2097.txt	0	14	perform	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	15	smaller	JJR	(NP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	16	,	,	*	-	-	-	-	*	-
en_2097.txt	0	17	better-targeted	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	18	clinical	JJ	*	-	-	-	-	*	-
en_2097.txt	0	19	studies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	20	in	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	21	order	NN	*	-	-	-	-	*	-
en_2097.txt	0	22	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	23	demonstrate	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	24	efficacy	NN	(NP*))))))))))	-	-	-	-	*	-
en_2097.txt	0	25	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	any	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	2	kind	NN	*)	-	-	-	-	*	-
en_2097.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	4	experiment	NN	(NP*))))	-	-	-	-	*	-
en_2097.txt	0	5	,	,	*	-	-	-	-	*	-
en_2097.txt	0	6	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	7	fundamental	JJ	*	-	-	-	-	*	-
en_2097.txt	0	8	principle	NN	*)	-	-	-	-	*	-
en_2097.txt	0	9	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	11	the	DT	(S(X*	-	-	-	-	*	-
en_2097.txt	0	12	greater	JJR	*	-	-	-	-	*	-
en_2097.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	14	number	NN	*)	-	-	-	-	*	-
en_2097.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	16	subjects	NNS	(NP*	-	-	-	-	*	-
en_2097.txt	0	17	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	18	iterations	NNS	*)))	-	-	-	-	*	-
en_2097.txt	0	19	,	,	*	-	-	-	-	*	-
en_2097.txt	0	20	the	DT	(X*	-	-	-	-	*	-
en_2097.txt	0	21	greater	JJR	*)	-	-	-	-	*	-
en_2097.txt	0	22	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	23	confidence	NN	*)	-	-	-	-	*	-
en_2097.txt	0	24	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	25	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	26	study	NN	*)))	-	-	-	-	*	-
en_2097.txt	0	27	'	''	*)	-	-	-	-	*	-
en_2097.txt	0	28	s	PRP	(NP*)	-	-	-	-	*	-
en_2097.txt	0	29	results	VBZ	(VP*))))	-	-	-	-	*	-
en_2097.txt	0	30	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Unless	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_2097.txt	0	1	the	DT	(S(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	2	effect	NN	*)	-	-	-	-	*	-
en_2097.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	4	the	DT	(NP*	-	-	-	-	*	(4
en_2097.txt	0	5	intervention	NN	*)))	-	-	-	-	*	4)
en_2097.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	profound	JJ	(ADJP*))))	-	-	-	-	*	-
en_2097.txt	0	8	,	,	*	-	-	-	-	*	-
en_2097.txt	0	9	small	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	10	studies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	11	generally	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	12	have	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	13	large	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	14	uncertainties	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	15	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	16	results	NNS	(NP*))))	-	-	-	-	*	-
en_2097.txt	0	17	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	That	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	1	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	2	where	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_2097.txt	0	3	biomarkers	NNS	(S(NP*)	-	-	-	-	*	(10)
en_2097.txt	0	4	make	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	6	difference	NN	*)))))	-	-	-	-	*	-
en_2097.txt	0	7	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	They	PRP	(TOP(S(NP*)	-	-	-	-	*	(10)
en_2097.txt	0	1	can	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	2	help	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	drug	NN	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	4	makers	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	5	to	TO	(VP*	-	-	-	-	*	-
en_2097.txt	0	6	design	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	clinical	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	8	studies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	9	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	10	will	MD	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	11	show	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	a	DT	(NP(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	13	high	JJ	*	-	-	-	-	*	-
en_2097.txt	0	14	``	``	*	-	-	-	-	*	-
en_2097.txt	0	15	relative	JJ	*	-	-	-	-	*	-
en_2097.txt	0	16	treatment	NN	*	-	-	-	-	*	-
en_2097.txt	0	17	difference	NN	*	-	-	-	-	*	-
en_2097.txt	0	18	''	''	*)	-	-	-	-	*	-
en_2097.txt	0	19	between	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	20	the	DT	(NP(NP*	-	-	-	-	*	(1
en_2097.txt	0	21	drug	NN	*)	-	-	-	-	*	1)
en_2097.txt	0	22	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	23	whatever	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	24	it	PRP	(S(NP*)	-	-	-	-	*	(1)
en_2097.txt	0	25	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	26	being	VBG	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	compared	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	28	to	TO	(S(VP*))))))))))	-	-	-	-	*	-
en_2097.txt	0	29	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2097.txt	0	30	often	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	31	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	32	placebo	NN	*)	-	-	-	-	*	-
en_2097.txt	0	33	,	,	*	-	-	-	-	*	-
en_2097.txt	0	34	but	CC	(CONJP*	-	-	-	-	*	-
en_2097.txt	0	35	sometimes	RB	*)	-	-	-	-	*	-
en_2097.txt	0	36	another	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	37	treatment	NN	*))	-	-	-	-	*	-
en_2097.txt	0	38	-RRB-	-RRB-	*))))))))))))	-	-	-	-	*	-
en_2097.txt	0	39	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Thus	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	when	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_2097.txt	0	3	drugs	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	ultimately	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	6	approved	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	based	VBN	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	on	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	10	use	NN	*)	-	-	-	-	*	-
en_2097.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	12	biomarkers	NNS	(NP*)))))))))	-	-	-	-	*	-
en_2097.txt	0	13	,	,	*	-	-	-	-	*	-
en_2097.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	15	description	NN	*)	-	-	-	-	*	-
en_2097.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	17	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	18	medication	NN	*)))	-	-	-	-	*	-
en_2097.txt	0	19	'	''	*	-	-	-	-	*	-
en_2097.txt	0	20	s	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	21	approved	JJ	(SBAR(S(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	22	uses	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	23	,	,	*	-	-	-	-	*	-
en_2097.txt	0	24	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	25	is	VBZ	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	26	printed	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	on	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	28	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	29	label	NN	*))))))	-	-	-	-	*	-
en_2097.txt	0	30	,	,	*)	-	-	-	-	*	-
en_2097.txt	0	31	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	32	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	33	more	RBR	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	34	restrictive	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	35	–	SYM	(S(SBAR(X*)	-	-	-	-	*	-
en_2097.txt	0	36	that	DT	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	37	is	VBZ	(VP*)))	-	-	-	-	*	-
en_2097.txt	0	38	,	,	*	-	-	-	-	*	-
en_2097.txt	0	39	it	PRP	(NP*)	-	-	-	-	*	-
en_2097.txt	0	40	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	41	reduce	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	42	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	43	size	NN	*)	-	-	-	-	*	-
en_2097.txt	0	44	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	45	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	46	patient	JJ	*	-	-	-	-	*	-
en_2097.txt	0	47	population	NN	*)	-	-	-	-	*	-
en_2097.txt	0	48	for	IN	(SBAR(WHPP*	-	-	-	-	*	-
en_2097.txt	0	49	which	WDT	(WHNP*))	-	-	-	-	*	-
en_2097.txt	0	50	the	DT	(S(NP*	-	-	-	-	*	(1
en_2097.txt	0	51	drug	NN	*)	-	-	-	-	*	1)
en_2097.txt	0	52	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	53	intended	JJ	(ADJP*)))))))))))))))	-	-	-	-	*	-
en_2097.txt	0	54	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	example	NN	(NP*))	-	-	-	-	*	-
en_2097.txt	0	2	,	,	*	-	-	-	-	*	-
en_2097.txt	0	3	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	4	drug	NN	*)	-	-	-	-	*	-
en_2097.txt	0	5	broadly	RB	(VP(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	6	approved	VBN	*	-	-	-	-	*	-
en_2097.txt	0	7	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	``	``	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	9	arthritis	NN	*	-	-	-	-	*	-
en_2097.txt	0	10	''	''	*	-	-	-	-	*	-
en_2097.txt	0	11	–	NN	*	-	-	-	-	*	-
en_2097.txt	0	12	inflammation	NN	*)	-	-	-	-	*	-
en_2097.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	14	joints	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	15	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	16	may	MD	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	17	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	due	JJ	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_2097.txt	0	20	dozens	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	22	different	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	23	disease	NN	*	-	-	-	-	*	-
en_2097.txt	0	24	processes	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	25	–	SYM	(X*))))))))))))))	-	-	-	-	*	-
en_2097.txt	0	26	can	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	28	more	RBR	(VP(ADVP*	-	-	-	-	*	-
en_2097.txt	0	29	widely	RB	*)	-	-	-	-	*	-
en_2097.txt	0	30	marketed	VBN	*	-	-	-	-	*	-
en_2097.txt	0	31	than	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	32	one	NN	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	33	approved	VBD	(VP*	-	-	-	-	*	-
en_2097.txt	0	34	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	35	treat	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	36	only	RB	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	37	the	DT	*	-	-	-	-	*	-
en_2097.txt	0	38	arthritis	NN	*)	-	-	-	-	*	-
en_2097.txt	0	39	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	40	accompanies	VBZ	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	41	psoriasis	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	42	or	CC	*	-	-	-	-	*	-
en_2097.txt	0	43	gout	NN	*))))))))))))))	-	-	-	-	*	-
en_2097.txt	0	44	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	reality	NN	(NP*))	-	-	-	-	*	-
en_2097.txt	0	2	,	,	*	-	-	-	-	*	-
en_2097.txt	0	3	however	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	4	,	,	*	-	-	-	-	*	-
en_2097.txt	0	5	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	6	situation	NN	*)	-	-	-	-	*	-
en_2097.txt	0	7	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	8	more	RBR	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	9	complex	JJ	*))	-	-	-	-	*	-
en_2097.txt	0	10	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Assessments	NNS	(TOP(S(S(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	1	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	2	safety	NN	(NP*	-	-	-	-	*	-
en_2097.txt	0	3	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	4	efficacy	NN	*)))	-	-	-	-	*	-
en_2097.txt	0	5	often	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	6	do	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	7	not	RB	*	-	-	-	-	*	-
en_2097.txt	0	8	move	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	9	closely	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	tandem	NN	(NP*))	-	-	-	-	*	-
en_2097.txt	0	12	,	,	*	-	-	-	-	*	-
en_2097.txt	0	13	so	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	14	that	IN	*	-	-	-	-	*	-
en_2097.txt	0	15	even	RB	(S(SBAR*	-	-	-	-	*	-
en_2097.txt	0	16	if	IN	*	-	-	-	-	*	-
en_2097.txt	0	17	smaller	JJR	(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	18	,	,	*	-	-	-	-	*	-
en_2097.txt	0	19	better-targeted	JJ	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	20	clinical	JJ	*	-	-	-	-	*	-
en_2097.txt	0	21	trials	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	22	offer	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	23	clear	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	24	evidence	NN	*)	-	-	-	-	*	-
en_2097.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	26	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	27	drug	NN	*)))))	-	-	-	-	*	-
en_2097.txt	0	28	'	:	*	-	-	-	-	*	-
en_2097.txt	0	29	s	PRP	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	30	efficacy	VBP	(VP*))))	-	-	-	-	*	-
en_2097.txt	0	31	,	,	*	-	-	-	-	*	-
en_2097.txt	0	32	regulators	NNS	(NP*)	-	-	-	-	*	-
en_2097.txt	0	33	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	34	demand	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	35	far	RB	(NP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	36	larger	JJR	*)	-	-	-	-	*	-
en_2097.txt	0	37	studies	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	38	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	39	provide	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	40	evidence	NN	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	41	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	42	the	DT	(NP*	-	-	-	-	*	(1
en_2097.txt	0	43	drug	NN	*)))))))))))))	-	-	-	-	*	1)
en_2097.txt	0	44	'	:	*	-	-	-	-	*	-
en_2097.txt	0	45	s	VBZ	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	46	safety	NN	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	47	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Increasingly	RB	(TOP(S(S(ADJP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	1	defensive	JJ	*	-	-	-	-	*	-
en_2097.txt	0	2	about	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	3	accusations	NNS	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	4	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	5	drugs	NNS	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	6	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	7	vaccines	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	8	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	9	inadequately	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	10	tested	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	11	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	12	safety	NN	(NP*))))))))	-	-	-	-	*	-
en_2097.txt	0	13	,	,	*	-	-	-	-	*	-
en_2097.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	recent	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	16	years	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	17	safety-obsessed	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	18	regulators	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	19	have	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	20	required	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	21	massive	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	22	,	,	*	-	-	-	-	*	-
en_2097.txt	0	23	hugely	RB	(ADJP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	24	expensive	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	25	,	,	*	-	-	-	-	*	-
en_2097.txt	0	26	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	27	time-consuming	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	28	clinical	JJ	*	-	-	-	-	*	-
en_2097.txt	0	29	trials	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	30	designed	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	31	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	32	detect	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	33	even	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	34	very	RB	(NP(ADJP*	-	-	-	-	*	-
en_2097.txt	0	35	rare	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	36	side	NN	*	-	-	-	-	*	-
en_2097.txt	0	37	effects	NNS	*))))))))	-	-	-	-	*	-
en_2097.txt	0	38	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Consider	VB	(TOP(FRAG(INTJ*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	for	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	3	example	NN	(NP*))	-	-	-	-	*	(11)
en_2097.txt	0	4	,	,	*	-	-	-	-	*	-
en_2097.txt	0	5	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	6	before	IN	(S(PP*	-	-	-	-	*	-
en_2097.txt	0	7	its	PRP$	(NP*	-	-	-	-	*	(11)
en_2097.txt	0	8	US	NNP	*	-	-	-	-	*	-
en_2097.txt	0	9	approval	NN	*))	-	-	-	-	*	-
en_2097.txt	0	10	,	,	*	-	-	-	-	*	-
en_2097.txt	0	11	a	DT	(NP(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	12	vaccine	NN	*)	-	-	-	-	*	-
en_2097.txt	0	13	against	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	14	rotavirus	NN	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	15	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_2097.txt	0	16	a	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	17	common	JJ	*	-	-	-	-	*	-
en_2097.txt	0	18	,	,	*	-	-	-	-	*	-
en_2097.txt	0	19	sometimes	RB	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	20	fatal	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	21	gastrointestinal	JJ	*	-	-	-	-	*	-
en_2097.txt	0	22	infection	NN	*)	-	-	-	-	*	-
en_2097.txt	0	23	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	24	children	NNS	(NP*)))	-	-	-	-	*	-
en_2097.txt	0	25	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_2097.txt	0	26	was	VBD	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	tested	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	28	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	29	more	JJR	(NP(QP*	-	-	-	-	*	-
en_2097.txt	0	30	than	IN	*	-	-	-	-	*	-
en_2097.txt	0	31	72,000	CD	*)	-	-	-	-	*	-
en_2097.txt	0	32	children	NNS	*))))))	-	-	-	-	*	-
en_2097.txt	0	33	–	SYM	(X*)	-	-	-	-	*	-
en_2097.txt	0	34	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	35	another	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	36	40,000-plus	JJ	*)	-	-	-	-	*	-
en_2097.txt	0	37	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	38	post-marketing	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	39	studies	NNS	*)))	-	-	-	-	*	-
en_2097.txt	0	40	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	On	IN	(TOP(S(PP*	-	-	-	-	*	-
en_2097.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	2	similar	JJ	*	-	-	-	-	*	-
en_2097.txt	0	3	scale	NN	*))	-	-	-	-	*	-
en_2097.txt	0	4	,	,	*	-	-	-	-	*	-
en_2097.txt	0	5	a	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	6	vaccine	NN	*	-	-	-	-	*	-
en_2097.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	8	prevent	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	9	human	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	10	papilloma	NN	*	-	-	-	-	*	-
en_2097.txt	0	11	virus	NN	*	-	-	-	-	*	-
en_2097.txt	0	12	infection	NN	*)	-	-	-	-	*	-
en_2097.txt	0	13	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	14	cervical	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	15	cancer	NN	*))))))	-	-	-	-	*	-
en_2097.txt	0	16	was	VBD	(VP*	-	-	-	-	*	-
en_2097.txt	0	17	tested	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	19	almost	RB	(NP(QP*	-	-	-	-	*	-
en_2097.txt	0	20	30,000	CD	*)	-	-	-	-	*	-
en_2097.txt	0	21	young	JJ	*	-	-	-	-	*	-
en_2097.txt	0	22	women	NNS	*))))	-	-	-	-	*	-
en_2097.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Such	JJ	(TOP(S(S(NP*	-	-	-	-	*	(12
en_2097.txt	0	1	studies	NNS	*)	-	-	-	-	*	12)
en_2097.txt	0	2	are	VBP	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	very	RB	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	4	costly	JJ	*)))	-	-	-	-	*	-
en_2097.txt	0	5	,	,	*	-	-	-	-	*	-
en_2097.txt	0	6	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	7	,	,	*	-	-	-	-	*	-
en_2097.txt	0	8	by	IN	(S(PP*	-	-	-	-	*	-
en_2097.txt	0	9	any	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	10	reasonable	JJ	*	-	-	-	-	*	-
en_2097.txt	0	11	standard	NN	*))	-	-	-	-	*	-
en_2097.txt	0	12	,	,	*	-	-	-	-	*	-
en_2097.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	14	number	NN	*)	-	-	-	-	*	-
en_2097.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	16	patients	NNS	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	17	included	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	19	them	PRP	(NP*))))))	-	-	-	-	*	(12)
en_2097.txt	0	20	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	21	grossly	RB	(ADJP*	-	-	-	-	*	-
en_2097.txt	0	22	excessive	JJ	*)))	-	-	-	-	*	-
en_2097.txt	0	23	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	Thus	RB	(TOP(S(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	1	,	,	*	-	-	-	-	*	-
en_2097.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	3	impact	NN	*)	-	-	-	-	*	-
en_2097.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	5	personalized	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	6	medicine	NN	*))	-	-	-	-	*	-
en_2097.txt	0	7	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	8	the	DT	(NP*	-	-	-	-	*	(13
en_2097.txt	0	9	short	JJ	*	-	-	-	-	*	-
en_2097.txt	0	10	term	NN	*)))	-	-	-	-	*	13)
en_2097.txt	0	11	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	13	positive	JJ	(ADJP*)	-	-	-	-	*	-
en_2097.txt	0	14	at	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	15	the	DT	(NP*	-	-	-	-	*	-
en_2097.txt	0	16	patient	NN	*)))))	-	-	-	-	*	-
en_2097.txt	0	17	'	:	*	-	-	-	-	*	-
en_2097.txt	0	18	s	PRP	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	19	bedside	VBP	(VP*))	-	-	-	-	*	-
en_2097.txt	0	20	,	,	*	-	-	-	-	*	-
en_2097.txt	0	21	but	CC	*	-	-	-	-	*	-
en_2097.txt	0	22	vast	JJ	(S(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	23	clinical	JJ	*	-	-	-	-	*	-
en_2097.txt	0	24	trials	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	25	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_2097.txt	0	26	demonstrate	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	28	safety	NN	*)	-	-	-	-	*	-
en_2097.txt	0	29	of	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	30	new	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	31	drugs	NNS	*))))))))	-	-	-	-	*	-
en_2097.txt	0	32	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	33	impose	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	34	huge	JJ	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	35	development	NN	*	-	-	-	-	*	-
en_2097.txt	0	36	costs	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	37	that	IN	(SBAR*	-	-	-	-	*	-
en_2097.txt	0	38	manufacturers	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	39	might	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	40	never	RB	(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	41	recover	VB	(VP*))))))))	-	-	-	-	*	-
en_2097.txt	0	42	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	-LRB-	-LRB-	(TOP(S*	-	-	-	-	*	-
en_2097.txt	0	1	Currently	RB	(S(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	2	,	,	*	-	-	-	-	*	-
en_2097.txt	0	3	only	RB	(NP(QP*	-	-	-	-	*	-
en_2097.txt	0	4	about	IN	*	-	-	-	-	*	-
en_2097.txt	0	5	one	CD	*	-	-	-	-	*	-
en_2097.txt	0	6	in	IN	*	-	-	-	-	*	-
en_2097.txt	0	7	five	CD	*)	-	-	-	-	*	-
en_2097.txt	0	8	drugs	NNS	*)	-	-	-	-	*	-
en_2097.txt	0	9	approved	VBN	(VP*	-	-	-	-	*	-
en_2097.txt	0	10	by	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	11	US	NNP	(NP(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	12	regulators	NNS	(PRN(S(NP*)	-	-	-	-	*	(14)
en_2097.txt	0	13	ever	RB	(VP(ADVP*)	-	-	-	-	*	-
en_2097.txt	0	14	recoup	VB	*	-	-	-	-	*	-
en_2097.txt	0	15	their	PRP$	(NP*	-	-	-	-	*	(14)
en_2097.txt	0	16	development	NN	*	-	-	-	-	*	-
en_2097.txt	0	17	costs	NNS	*))	-	-	-	-	*	-
en_2097.txt	0	18	.	.	*)	-	-	-	-	*	-
en_2097.txt	0	19	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_2097.txt	0	20	&	CC	*	-	-	-	-	*	-
en_2097.txt	0	21	#	#	(NP*	-	-	-	-	*	-
en_2097.txt	0	22	160	CD	*)))))	-	-	-	-	*	-
en_2097.txt	0	23	;	:	*	-	-	-	-	*	-
en_2097.txt	0	24	This	DT	(S(NP*	-	-	-	-	*	-
en_2097.txt	0	25	situation	NN	*)	-	-	-	-	*	-
en_2097.txt	0	26	would	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	27	not	RB	*	-	-	-	-	*	-
en_2097.txt	0	28	be	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	29	sustainable	JJ	(ADJP*)	-	-	-	-	*	-
en_2097.txt	0	30	in	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	31	the	DT	(NP*	-	-	-	-	*	(13
en_2097.txt	0	32	long	JJ	*	-	-	-	-	*	-
en_2097.txt	0	33	term	NN	*)))))	-	-	-	-	*	13)
en_2097.txt	0	34	.	.	*))	-	-	-	-	*	-

en_2097.txt	0	0	If	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_2097.txt	0	1	society	NN	(S(NP*)	-	-	-	-	*	(15)
en_2097.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_2097.txt	0	3	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	4	derive	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_2097.txt	0	6	maximum	JJ	*	-	-	-	-	*	-
en_2097.txt	0	7	benefit	NN	*)	-	-	-	-	*	-
en_2097.txt	0	8	from	IN	(PP*	-	-	-	-	*	-
en_2097.txt	0	9	personalized	JJ	(NP*	-	-	-	-	*	-
en_2097.txt	0	10	medicine	NN	*)))))))))	-	-	-	-	*	-
en_2097.txt	0	11	–	SYM	(NP(NP*)	-	-	-	-	*	-
en_2097.txt	0	12	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_2097.txt	0	13	will	MD	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	14	require	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	15	companies	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	16	to	TO	(VP*	-	-	-	-	*	-
en_2097.txt	0	17	pursue	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	18	it	PRP	(NP*)	-	-	-	-	*	(15)
en_2097.txt	0	19	–	SYM	(SBAR(X*)	-	-	-	-	*	-
en_2097.txt	0	20	regulators	NNS	(S(NP*)	-	-	-	-	*	-
en_2097.txt	0	21	worldwide	VBP	(VP*)))))))))))	-	-	-	-	*	-
en_2097.txt	0	22	will	MD	(VP*	-	-	-	-	*	-
en_2097.txt	0	23	need	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	24	to	TO	(S(VP*	-	-	-	-	*	-
en_2097.txt	0	25	adopt	VB	(VP*	-	-	-	-	*	-
en_2097.txt	0	26	reasoned	VBN	(NP*	-	-	-	-	*	-
en_2097.txt	0	27	and	CC	*	-	-	-	-	*	-
en_2097.txt	0	28	reasonable	JJ	*	-	-	-	-	*	-
en_2097.txt	0	29	policies	NNS	*))))))	-	-	-	-	*	-
en_2097.txt	0	30	.	.	*))	-	-	-	-	*	-

#end document
